Similar Articles |
|
Pharmaceutical Executive March 3, 2014 Sillup & Porth |
Pharm Exec: Annual Press Audit 2014 Pharm Exec's latest survey of press issues shows that media coverage continues to remain on balance negative toward the industry, by a slight margin: 47% this year compared to a 46% average over the last seven years. |
Pharmaceutical Executive March 1, 2012 Sillup & Porth |
Pharma & The Press Our eighth annual press audit finds the industry out of the crosshairs for now. |
Pharmaceutical Executive March 1, 2009 Porth & Sillup |
Fifth Annual Press Audit: Safety in the Spotlight Reporters pass on the typical litany of lightning-rod issues and instead devote more than three-quarters of all coverage in 2008 to drug safety and the regulators who enforce it. |
Pharmaceutical Executive February 1, 2006 Porth & Sillup |
Annual Press Audit: Front Page Pharma Newspapers in a study pool published more than twice as many front-page and editorial-page stories on the pharmaceutical industry than they did last year. |
Pharmaceutical Executive April 1, 2007 Porth & Sillup |
Media Audit: Stop the Presses! The media are becoming more negative and one-sided when it comes to reporting pharmaceutical industry news. |
Pharmaceutical Executive March 1, 2011 |
Pharm Exec's Seventh Annual Media Audit Negative views regarding pharma are on the rise, but vaccines help keep the focus on the positives of innovation. |
Pharmaceutical Executive April 1, 2009 Jill Wechsler |
Kickoff for Reform In addition to overhauling healthcare, Congress is weighing proposals for updating FDA policies and expanding access to drugs. |
Chemistry World March 25, 2010 Rebecca Trager |
Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'. |
Pharmaceutical Executive December 1, 2008 Jill Wechsler |
Challenge and Challenges Expanded healthcare coverage also fits the goals of pharma manufacturers. |
Searcher October 2010 Stephanie C. Ardito |
The Medical Digital: U.S. Healthcare Reform: A Follow-Up For those interested in serious, scholarly research regarding the historical progress of U.S. healthcare reform, this column and my prior column might be a good pairing for neutral sources. |
Pharmaceutical Executive January 1, 2013 Jill Wechsler |
Transformation to Characterize 2013 FDA policies will reshape drug development, while pressure to cut healthcare spending may alter drug coverage and pricing. |
Pharmaceutical Executive January 1, 2009 Walter Armstrong |
Up in the Air If pharma execs start upping their consumption of antihypertensives and anxiolytics (all branded, of course) in the months to come, it won't be a huge surprise. The industry faces a truly unprecedented number of political and policy challenges. |
Pharmaceutical Executive April 10, 2014 |
Obama Policies Reshape Pharma Marketing Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler. |
Pharmaceutical Executive June 1, 2007 Stan Bernard |
Consumerization: Pandora's Pillbox By going direct-to-consumer, the industry unwittingly unleashed a swarm of opportunities for other players to enter the pharmaceutical fray. And they made the most of it. Now, a decade later, pharma is feeling the fallout in consumer trust and product value. It's time to take back control. |
Pharmaceutical Executive December 1, 2012 Jill Wechsler |
Obamacare, Innovation and Pricing Tax and budget decisions will shape the healthcare market and drug research and regulation. |
Pharmaceutical Executive October 1, 2006 |
Sales and Marketing: Where the Buck Stops Pharma's ultimate customer is the employer - the guy who pays the health plan's bill. Here's what he wants to know about drugs. |
ONLINE May/Jun 2003 Hal Kirkwood |
Analyze That: LexisNexis Media Analyzer Media Analyzer is a new and interesting company and media database from LexisNexis. Its ability to analyze both textually and graphically how media sources cover companies, sectors, and news topics will find many practical applications in business, communications, and journalism. |
Pharmaceutical Executive January 1, 2011 |
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade. |
Pharmaceutical Executive September 1, 2012 Jill Wechsler |
Costs, Coverage, and Court Decisions Its election season and drug pricing issues are once again front and center in the policy wars on managing the high cost of healthcare. |
Nursing Management April 2011 Deborah E. Trautman |
Healthcare Reform: 1 Year Later A year after the Patient Protection and Affordable Care Act was signed into law, the nation remains divided. |
Pharmaceutical Executive April 1, 2011 |
Revisiting Reform Courts, Congress review policies and programs shaping drug costs and access. |
Pharmaceutical Executive January 1, 2012 Jill Wechsler |
New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation. |
Pharmaceutical Executive February 1, 2011 Jon Zifferblat |
China: Business as UNusual If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshot of what's ahead for Big Pharma in the country |
The Motley Fool May 12, 2009 Brian Orelli |
Your Company Is Giving Away Revenue Bad news for investors in the health-care industry: the companies you invest in just pledged to give back 1.5% of their expected U.S. revenue growth to President Obama. |
Pharmaceutical Executive April 1, 2012 |
Medical Meetings: Docs Speak Out Three physicians took the stage at the fourth annual West Coast Life Sciences Meeting Management Forum to explain their perspective on healthcare reform, online versus live education, and more. |
Pharmaceutical Executive August 1, 2008 |
Harbingers of Change The pharmaceutical industry is changing. Here are eight seminal events that describe how. |
Investment Advisor July 2009 Melanie Waddell |
The Great Health Reform Debate President Barack Obama has set an ambitious deadline of October to achieve comprehensive healthcare reform. |
Pharmaceutical Executive October 1, 2011 Jill Wechsler |
An 'A' for Advancing Expectations As head of both the Food and Drug Administration and the Centers for Medicare and Medicaid Services, Mark McClellan has been at the center of public policy affecting the pharmaceutical industry over the last decade. |
Reason April 2008 Ronald Bailey |
Medical Speech As a 1997 law expires, the FDA is mulling a plan allowing companies to disseminate unabridged reprints of "truthful and non-misleading" medical journal articles describing "off-label" uses of approved medications to physicians. |
Pharmaceutical Executive January 1, 2012 William Looney |
Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap. |
Pharmaceutical Executive December 1, 2010 Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
Search Engine Watch August 2, 2000 Danny Sullivan |
Breaking The News Barrier Moreover and Yahoo go a step ordinary news search engines, because they pick up headlines from subject-oriented sites that even news search engines may miss. Those interested in news should try either Moreover or Yahoo, because of the breadth of coverage they offer. |
Pharmaceutical Executive January 1, 2007 Walter Armstrong |
Forecast 2007: At Sea In times of crisis, it's harder than ever to take the long view. The healing arts may be as old as humankind, but the business of pharma is still in its infancy. |
Pharmaceutical Executive December 1, 2005 Patrick Clinton |
PharmExec's 2006 Forecast The 2006 pharmaceutical industry is under assault from Congress, the press and the public, add a complex government program that will unimaginably change industry economics, and subtract revenues from off-patent products. |
Pharmaceutical Executive February 1, 2012 Jill Wechsler |
Costs and Benefits of Health Reform Will expanded markets and accountable care organizations offset higher rebates, added fees, and closer scrutiny of marketing and prices? |
Pharmaceutical Executive February 1, 2006 Chandler & Chicco |
Public Relations: Damage Control Unless pharma defines a compelling story, and defends it vigorously in the consumer marketplace, others will enter that vacuum and tell the story for it -- in far less flattering ways |
Pharmaceutical Executive May 1, 2009 |
Ad(Ventures) in Pharmaland Despite the downside in ad spend, an upside remains in the digital space that's wide open for exploration. |
Pharmaceutical Executive July 3, 2007 Humphrey Taylor |
Opinion: Lead, Follow, or Get Out of the Way A comparative-effectiveness board is coming. The pharmaceutical industry's wise will embrace the change. |
Pharmaceutical Executive December 1, 2010 Jill Wechsler |
New Ballgame in Washington Republican gains in Congress create uncertainty for health reform, drug regulation, and biomedical research |
The Motley Fool September 20, 2007 Brian Orelli |
Winners and Losers in Universal Health Care Here's a look at the companies that stand to win or lose if Hillary Rodham Clinton is elected -- and gets her three-pronged health-care reform plan through Congress. |
Pharmaceutical Executive October 1, 2010 |
When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve? |
Pharmaceutical Executive February 1, 2009 Jill Wechsler |
Securing Savings A close look at the healthcare industry will separate real cost-cutting measures from money-saving myths. |
Pharmaceutical Executive January 1, 2014 Jill Wechsler |
Pharma Challenges for 2014 Pricing and personalized medicine are key themes shaping drug development and marketing |
Pharmaceutical Executive June 1, 2005 Zimmerman & Fay |
Marketing to Professionals: Dr. Ambassador The pharma industry is under siege in the news media. Smart companies must create a role for physicians as ambassadors who can raise patient confidence in drugs and the pharma industry as a whole. |
Pharmaceutical Executive July 1, 2009 |
The Pharmerging Future A guide to grabbing growth in seven "pharmerging" markets. |
Pharmaceutical Executive October 1, 2008 Jill Wechsler |
Part D Under Attack Congressional leaders ready campaign to curb Medicare drug plans. |
Investment Advisor October 2009 Melanie Waddell |
Danger & Opportunity: Healthcare Reform Picks Up Momentum Healthcare reform is still moving ahead, despite opposition from Republicans and well-covered populist discontent over the plan. |
Pharmaceutical Executive November 1, 2008 Patrick Clinton |
Pharm Exec Q&A: Tommy Thompson The former health secretary offers a reality check on healthcare reform and what to expect in '09. |
Chemistry World November 23, 2011 Helen Carmichael |
Nanotechnology risks get minimal press coverage A US study has found scant media coverage of the potential risks posed by nanotechnology, with many more articles extolling its future benefits. |
Pharmaceutical Executive April 10, 2014 Peter Houston |
Fixing Wikipedia Will Pharma join a growing effort to make the world's leading online health information resource more relevant to providers and safer for patients? |